New radiation method aims to improve sarcoma surgery outcomes

NCT ID NCT05224934

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This trial is testing a new type of radiation therapy given before surgery for retroperitoneal sarcoma, a rare cancer in the abdomen. The radiation is delivered in just five high-dose sessions, targeting the tumor and any nearby nodules. The goal is to see if this approach reduces complications during and after surgery, while still effectively treating the cancer. The study will enroll 50 adults whose tumors can be safely treated with this method.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
ultra-hypofractionated radiotherapy (stereotactic ablative radiotherapy)
What this could lead to
If successful, this could offer a more effective and safer way to treat retroperitoneal sarcoma before surgery, potentially reducing side effects and improving recovery.
What could go wrong
This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. The radiation dose is high and could cause unexpected side effects or complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RADIOTHERAPY SIDE EFFECT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.